Search

Your search keyword '"Gleevec (Medication)"' showing total 714 results
Start Over Descriptor "Gleevec (Medication)"
714 results on '"Gleevec (Medication)"'

1. Novartis AG Meet the Management - Final

Subjects
Novartis AG -- Management, Bank of America Corp. -- Management, Adalimumab, Special events, Company business management, Business, Pluvicto (Medication), Scemblix (Medication), Fabhalta (Medication), Entresto (Medication), Zolgensma (Medication), Gleevec (Medication), Kisqali (Medication), Leqvio (Medication)
Abstract

Presentation SLOAN SIMPSON, GLOBAL HEAD OF INVESTOR RELATIONS, NOVARTIS AG: Good morning, everyone, and welcome to the 2024 Meet Novartis Management event. Thank you so much for your time, your [...]

Published
2024

3. Q1 2024 Novartis AG Earnings Call - Final

Subjects
Novartis AG -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Business, Pluvicto (Medication), Scemblix (Medication), Cosentyx (Medication), Entresto (Medication), Gleevec (Medication), Kisqali (Medication), Leqvio (Medication)
Abstract

Presentation OPERATOR: Good morning and good afternoon, and welcome to the Novartis Q1 2024 Results Release Conference Call and live webcast. (Operator Instructions) The conference is being recorded. (Operator Instructions) [...]

Published
2024

4. Research Study Findings from Research Center for Hematology Update Understanding of Chronic Myelogenous Leukemia (The case of successful therapy with Nilotinib in patients with Ph-positive chronic myelogenous leukemia of chronic phase resistant ...)

Subjects
Oncology, Experimental, Antineoplastic agents, Nilotinib, Chronic myeloid leukemia -- Care and treatment, Cancer -- Research, Physical fitness, Antimitotic agents, Health, Gleevec (Medication)
Abstract

2023 APR 22 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New study results on chronic myelogenous leukemia have been published. According to [...]

Published
2023

5. Enliven Therapeutics Inc at Goldman Sachs Healthcare Conference - Final

Subjects
The Goldman Sachs Group Inc. -- Conferences, meetings and seminars, Novartis AG -- Conferences, meetings and seminars, Investment banks -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Business, Enhertu (Medication), Scemblix (Medication), Gleevec (Medication)
Abstract

Presentation SALVEEN RICHTER, ANALYST, GOLDMAN SACHS GROUP, INC.: Good morning, everyone, and thanks so much for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs. I'm really pleased to [...]

Published
2023

6. Inhibikase Therapeutics Inc at LD Micro Invitational Conference - Final

Subjects
Nilotinib -- Conferences, meetings and seminars, Business, Gleevec (Medication)
Abstract

Presentation UNIDENTIFIED PARTICIPANT: Presentation with an advocate therapeutics is from Mr. Milton Werner. MILTON WERNER, PRESIDENT & CEO, INHIBIKASE THERAPEUTICS, INC.: I see that you're in some applause at the [...]

Published
2023

7. Research on Gastrointestinal Stromal Tumors Detailed by Researchers at First Affiliated Hospital of Zhejiang University (Progress in the treatment of gastrointestinal stromal tumors)

Subjects
Gleevec (Medication), Drug therapy, Research, Physical fitness, Gastrointestinal system, Tumors -- Research -- Drug therapy, Platelet-derived growth factor, Stem cells, Genes, Obesity, Anopheles, Editors
Abstract

2020 MAR 28 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New research on gastrointestinal stromal tumors is the subject of a new [...]

Published
2020

8. Lupin launches generic Gleevec tablets in US market

Subjects
United States. Food and Drug Administration, Novartis Pharmaceuticals Corp., Generic drugs, Pharmaceutical industry, Antineoplastic agents, Pediatrics, Pharmaceuticals and cosmetics industries, Gleevec (Medication)
Abstract

Byline: Our Bureau Lupin Limited has launched imatinib mesylate tablets, 100 mg (base) and 400 mg (base). Lupin's alliance partner Natco had received an approval from the United States Food [...]

Published
2019

9. Breckenridge wins final US FDA approval for Imatinib Mesylate Tablets ANDA

Subjects
United States. Food and Drug Administration, Novartis AG, Pharmaceutical industry, General interest, News, opinion and commentary, Gleevec (Medication)
Abstract

Global Banking News-March 5, 2019-Breckenridge wins final US FDA approval for Imatinib Mesylate Tablets ANDA (C)2019 ENPublishing - http://www.enpublishing.co.uk Pharmaceutical company Breckenridge Pharmaceutical Inc reported on Monday the receipt of [...]

Published
2019

10. VERIFIED CLINICAL BENEFIT | CANCER ACCELERATED APPROVALS

Subjects
United States. Food and Drug Administration, Carboplatin, Metastasis, Antineoplastic agents, Chemotherapy, Cancer -- Chemotherapy, Monoclonal antibodies, BCR-ABL tyrosine kinase inhibitors, Antimitotic agents, News, opinion and commentary, Gleevec (Medication), Keytruda (Medication)
Abstract

SILVER SPRING, MD -- The following information was released by the U.S. Food and Drug Administration (FDA): This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications1 with [...]

Published
2021

11. Novartis AG R&D Day - Final

Subjects
Novartis Pharma AG, Novartis AG, Pharmaceutical industry, Business, Cosentyx (Medication), Entresto (Medication), Xolair (Medication), Zolgensma (Medication), Gleevec (Medication), Kymriah (Medication), Piqray (Medication), Soliris (Medication)
Abstract

Presentation SAMIR SHAH, GLOBAL HEAD OF IR, NOVARTIS AG: Welcome, everybody, and thank you for joining us today. Thank you also for all of the people who spent the entire [...]

Published
2019

13. Tasigna nilotinib; Novartis Drug Analysis 2018: An Orally Administered BCR-ABL Tyrosine Kinase Inhibitor - ResearchAndMarkets.com

Subjects
Novartis AG, Tasigna (Medication), Gleevec (Medication), Physical fitness, Tyrosine, Pharmaceutical industry, Antineoplastic agents, Phenols (Class of compounds), Proteins
Abstract

2018 MAR 10 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- The 'Drug analysis: Tasigna' drug pipelines has been added to ResearchAndMarkets.com's offering. [...]

Published
2018

16. Therapeutic focus: oncology: amid the din of drug-pricing tussles, rapid scientific advancements are nurturing individualized anticancer approaches and sharpening the view of cancer's underlying biology

Author

Knutsen, Rebecca Mayer

Subjects
Revlimid (Medication), Imbruvica (Medication), Rituxan (Medication), Herceptin (Medication), Alimta (Medication), Xgeva (Medication), Gleevec (Medication), Zytiga (Medication), Sprycel (Medication), Avastin (Medication), Health aspects, Product price, Pricing -- Health aspects, Cancer -- Health aspects
Abstract

SCIENCE-WISE, the oncology sector has been hitting it out of the park with solutions promising improved survival with lower toxicity for some patients. Alas, it's not all about the science: [...]

Published
2016

17. Oncology

Author

Knutsen, Rebecca Mayer

Subjects
Afinitor (Medication), Perjeta (Medication), Rituxan (Medication), Herceptin (Medication), Alimta (Medication), Yervoy (Medication), Gleevec (Medication), Zytiga (Medication), Sprycel (Medication), Avastin (Medication), Monoclonal antibodies, Chemotherapy, Immunotherapy, Pharmaceutical industry, Cancer -- Chemotherapy
Abstract

Today's cancer therapies have an unlikely champion in their corner: the immune system. Scientists are training the natural disease defender to KO cancer for good--and pharma companies are drooling over [...]

Published
2015

18. Teva announces prescription copay savings program for generic Gleevec in U.S

Subjects
Teva Pharmaceutical Industries Ltd. -- Laws, regulations and rules, Generic drugs -- Laws, regulations and rules, Pharmaceutical industry -- Laws, regulations and rules, Antineoplastic agents -- Laws, regulations and rules, Government regulation, Business, News, opinion and commentary, Gleevec (Medication)
Abstract

Teva Pharmaceuticals USA announced the launch of a prescription copay assistance program in the U.S. for the company's generic equivalent to Gleevec tablets. Teva launched imatinib mesylate tablets in the [...]

Published
2017

19. Mylan Launches Generic Gleevec[R] Tablets

Subjects
Novartis AG, United States. Food and Drug Administration, Gleevec (Medication), Physical fitness, Imatinib mesylate, Generic drugs, Pharmaceutical industry, Drug approval
Abstract

2017 OCT 21 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Mylan N.V. (NASDAQ, TASE: MYL) announced the U.S. launch of Imatinib Mesylate [...]

Published
2017

20. GST may impact healthcare companies adversely in Q1: ICICI Securities

Subjects
Goods and services tax, Pharmaceuticals and cosmetics industries, Gleevec (Medication)
Abstract

Byline: Our Bureau ICICI Securities has projected weak performance by healthcare companies in the first quarter ended June 2017 on account of GST implementation, competition and pricing pressure. ICICI expects [...]

Published
2017

21. Studies from National Cancer Institute Describe New Findings in Gleevec Therapy [Imatinib mesylate (Gleevec) inhibits Notch and c-Myc signaling: Five-day treatment permanently rescues mammary development]

Subjects
United States. National Cancer Institute, Gleevec (Medication), Genetic engineering, Physical fitness, Cancer, Imatinib mesylate, Cancer research
Abstract

2017 APR 8 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in Drugs and Therapies - Gleevec Therapy. According [...]

Published
2017

22. New Findings Reported from Rockefeller University Describe Advances in Alzheimer Disease (Gleevec shifts APP processing from a beta-cleavage to a nonamyloidogenic cleavage)

Subjects
Rockefeller University, National Academy of Sciences, Gleevec (Medication), Research, Physical fitness, Medical research, Antineoplastic agents -- Research, Alzheimer's disease -- Research, Amyloid beta-protein
Abstract

2017 MAR 18 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Neurodegenerative Diseases and Conditions - Alzheimer Disease. [...]

Published
2017

23. Q2 2018 Novartis AG Earnings Call - Final

Subjects
United States. Food and Drug Administration, Novartis Pharma AG -- Company sales and earnings, Novartis AG -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Business, Afinitor (Medication), Cosentyx (Medication), Entresto (Medication), Tasigna (Medication), Gilenya (Medication), Gleevec (Medication), Kymriah (Medication)
Abstract

Presentation OPERATOR: Good morning, and good afternoon, and welcome to the Novartis Q2 2018 Results Release Conference Call and Live Audio Webcast. (Operator Instructions) And the conference is being recorded. [...]

Published
2018

24. Test for the industry: progress toward drug/diagnostic combinations has been slow, but companion diagnostics are important to pharma's future

Author

Fitzsimmons, Lyle D.

Subjects
Genaissance Pharmaceuticals Inc., Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Gleevec (Medication), Herceptin (Medication), Tarceva (Medication)
Abstract

The approval of the breast-cancer drug Herceptin, along with a diagnostic test that would identify those patients most likely to respond to it, was assumed by many to mark the [...]

Published
2005

25. Rare diseases

Author

Knutsen, Rebecca Mayer

Subjects
Vertex Pharmaceuticals Inc., Advate (Medication), Avonex (Medication), Revlimid (Medication), Soliris (Medication), Rituxan (Medication), Rebif (Medication), Alimta (Medication), Velcade (Medication), Gleevec (Medication), Copaxone (Medication), Gene therapy, Immunotherapy, Pharmaceutical industry
Abstract

The rare disease drug market is making history with its steady growth and burgeoning pipeline--and owing to continuing breakthroughs in gene therapy, the biggest advances are yet to come. Rebecca [...]

Published
2015

27. Oncology

Author

Dysart, Joe

Subjects
Merck & Company Inc., Bristol-Myers Squibb Co., American Society of Clinical Oncology, Xeloda (Medication), Afinitor (Medication), Treanda (Medication), Rituxan (Medication), Yervoy (Medication), Herceptin (Medication), Alimta (Medication), Xgeva (Medication), Gleevec (Medication), Zytiga (Medication), Avastin (Medication), Immunotherapy, Pharmaceutical industry
Abstract

Immunotherapy is an emerging powerhouse in cancer treatment. Early gains being made in multiple tumor types provide a glimpse of the effectiveness of several agents and regimens. While longer follow-up [...]

Published
2014

28. Teva Announces Launch of Generic Gleevec[R] Tablets in the United States

Subjects
Teva Pharmaceutical Industries Ltd., Gleevec (Medication), Physical fitness, Imatinib mesylate, Generic drugs, Pharmaceutical industry, Drug approval
Abstract

2016 AUG 27 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) announced the launch of the [...]

Published
2016

29. Event Brief of Q4 2017 Novartis AG Earnings Call - Final

Subjects
Novartis Pharma AG -- Company sales and earnings, Novartis AG -- Company sales and earnings, Cowen and Company L.L.C. -- Company sales and earnings, Securities industry -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Securities industry, Company earnings/profit, Business, Cosentyx (Medication), Entresto (Medication), Gleevec (Medication), Kisqali (Medication), Kymriah (Medication)
Abstract

CORPORATE PARTICIPANTS . Bruno Strigini . Harry Kirsch - Novartis AG,CFO . Joseph Jimenez - Novartis AG,CEO . Paul Hudson - Novartis AG,CEO, Novartis Pharmaceuticals . Richard Francis - Novartis [...]

Published
2018

30. Q4 2017 Novartis AG Earnings Call - Final

Subjects
Novartis Oncology -- Company sales and earnings, Novartis AG -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Business, Cosentyx (Medication), Entresto (Medication), Gleevec (Medication), Kisqali (Medication), Kymriah (Medication)
Abstract

Presentation OPERATOR: Good morning and good afternoon, and welcome to the Novartis Q4 and Full Year 2017 Results Release Conference Call and Live Audio Webcast. (Operator Instructions) A recording of [...]

Published
2018

31. Rare diseases: 'New and improved' has entered this space. Alongside the existing compounds that are transforming the lives of patients with orphan ailments, a wave of incrementally better products is coming out. Noah Pines reviews the significant rare-disease market trends

Author

Pines, Noah

Subjects
Advate (Medication), Revlimid (Medication), Dvonex (Medication), Rituxan (Medication), Rebif (Medication), Tracleer (Medication), Alimta (Medication), Neulasta (Medication), Gleevec (Medication), Copaxone (Medication), Market size, Diagnosis, Market research, Care and treatment, Research, Health aspects, Forecasts and trends, Marketing research, Market trend/market analysis, Orphan drugs -- Market research -- Health aspects -- Forecasts and trends -- Market size, Rare diseases -- Diagnosis -- Care and treatment -- Research
Abstract

Orphan Drugs 2.0 has arrived. Manufacturers in this space are evolving their business models, from offering life-saving therapies to making available treatments that boost patient quality of life, as they [...]

Published
2014

32. Blueprint Medicines Corp at Morgan Stanley Healthcare Conference - Final

Subjects
Morgan Stanley -- Conferences, meetings and seminars, Securities industry -- Conferences, meetings and seminars, Health care industry -- Conferences, meetings and seminars, Health care industry, Securities industry, Business, Gleevec (Medication)
Abstract

Presentation ANDREW SCOTT BERENS, EXECUTIVE DIRECTOR, MORGAN STANLEY, RESEARCH DIVISION: Welcome to Day 3 of the Morgan Stanley Conference. I'm Andrew Berens, Senior Biotech Analyst. Before we get started, I [...]

Published
2017

33. Blueprint Medicines Corp at Canaccord Genuity Growth Conference - Final

Subjects
Conferences and conventions -- Conferences, meetings and seminars, Drugs -- Conferences, meetings and seminars, Business, Gleevec (Medication)
Abstract

Presentation ARLINDA LEE, ANALYST, CANACCORD GENUITY: Good morning, my name is Arlinda Lee and I am a biotech analyst at Canaccord. We are pleased to have Blueprint Medicines present and [...]

Published
2017

35. Q1 2017 Novartis AG Earnings Call - Final

Subjects
Novartis AG -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Business, Cosentyx (Medication), Entresto (Medication), Humira (Medication), Gilenya (Medication), Glatopa (Medication), Gleevec (Medication), Kisqali (Medication)
Abstract

Presentation OPERATOR: Good morning, and good afternoon, and welcome to the Novartis Q1 2017 Results Release Conference Call and Live Audio Webcast. (Operator Instructions) A recording of the conference call [...]

Published
2017

36. Oncology: as genetically targeted immunotherapies blaze a trail through mid- and late-stage clinical trials, the days of traditional chemotherapy in taming tumors may be numbered. Noah Pines on the race to market cancer drugs that harness the PD-1 pathway, other standouts in the oncology pipeline, plus what's already making waves in the market

Author

Pines, Noah

Subjects
Bristol-Myers Squibb Co., American Society of Clinical Oncology, Xeloda (Medication), Eloxatin (Medication), Rituxan (Medication), Herceptin (Medication), Alimta (Medication), Xgeva (Medication), Velcade (Medication), Gleevec (Medication), Avastin (Medication), Erbitux (Medication), Drug therapy, Chemotherapy, Tumors -- Drug therapy, Immunotherapy, Pharmaceutical industry, Antineoplastic agents, Cancer -- Chemotherapy, Antimitotic agents
Abstract

The data are still early, but the investigational PD-1s appear to be the Next Big Thing in oncology. By training the body's immune system to repel cancer cells, they've smashed [...]

Published
2013

37. Scientists probe cancer cell resistance: new insights may help development of new drugs

Author

Friedrich, M.J.

Subjects
Gleevec (Medication), Chronic myeloid leukemia -- Drug therapy, Drug resistance
Abstract

Researchers are trying to determine how cancer cells in patients with chronic myelogenous leukemia (CML) become resistant to the drug Gleevec so they can develop new drugs to overcome this resistance. Gleevec can be effective for treating CML, but many patients relapse. Many breast cancer patients taking tamoxifen also become resistant. Researchers need more tissue biopsies from these patients so they can determine how the cancer cells become resistant to cancer drugs.

Published
2003

38. Lupin in alliance with Natco receives FDA approval for Imatinib Mesylate Tablets

Subjects
United States. Food and Drug Administration, Natco Pharma Ltd. -- Alliances and partnerships, Novartis Pharmaceuticals Corp. -- Alliances and partnerships, Pharmaceutical industry -- Alliances and partnerships, Generic drugs, Imatinib mesylate, Pediatrics, Child health, Antineoplastic agents, General interest, News, opinion and commentary, Gleevec (Medication)
Abstract

New Delhi: Lupin Limited has issued the following press release: Pharma major Lupin Limited (Lupin) and Natco Pharma Limited (Natco) announced the final ANDA approval for Imatinib Mesylate Tablets, 100 [...]

Published
2019

39. Lupin in alliance with Natco receives FDA approval for Imatinib Mesylate Tablets

Subjects
United States. Food and Drug Administration, Novartis Pharmaceuticals Corp. -- Alliances and partnerships, Pharmaceutical industry -- Alliances and partnerships, Generic drugs, Imatinib mesylate, Pediatrics, Child health, Antineoplastic agents, Biotechnology industry, Gleevec (Medication)
Abstract

Imatinib Mesylate Tablets is the generic version of Novartis' Gleevec(R) Tablets Lupin and Natco Pharma has announced the final ANDA approval for Imatinib Mesylate Tablets, 100 mg (base) and 400 [...]

Published
2019

40. Breckenridge Announces Final Approval of its ANDA for Imatinib Mesylate Tablets (RLD: Gleevec(r))

Subjects
Novartis AG -- Planning, Pharmaceutical industry -- Planning, Drug approval, Imatinib mesylate -- Planning, Antineoplastic agents, Generic drugs, Company business planning, General interest, News, opinion and commentary, Gleevec (Medication)
Abstract

BOCA RATON: Breckenridge Pharmaceutical, Inc. has issued the following press release: Breckenridge Pharmaceutical, Inc. announced that the U.S. Food and Drug Administration has granted final approval for its Abbreviated New [...]

Published
2019

41. Lupin receives USFDA approval for Imatinib Mesylate Tablets

Subjects
United States. Food and Drug Administration, Novartis Pharmaceuticals Corp., Pharmaceutical industry, Generic drugs, Imatinib mesylate, Antineoplastic agents, Business, international, Gleevec (Medication)
Abstract

Imatinib Mesylate Tablets, 100 mg and 400 mg had annual sales of approximately $655 mn in the US Lupin in alliance with Natco Pharma has received final ANDA approval for [...]

Published
2019

42. Breckenridge Announces Final Approval of its ANDA for Imatinib Mesylate Tablets (RLD: Gleevec)

Subjects
Novartis AG -- Planning, Drug approval, Pharmaceutical industry -- Planning, Company business planning, Business, News, opinion and commentary, Gleevec (Medication)
Abstract

BOCA RATON, Fla., March 4, 2019 /PRNewswire/ --Breckenridge Pharmaceutical, Inc. announced that the U.S. Food and Drug Administration has granted final approval for its Abbreviated New Drug Application for Imatinib [...]

Published
2019

43. Oncology: personalized medicines that use companion diagnostics to identify a patient sub-population are the theme of this year's crop of cancer drug approvals. But they're no panacea for a healthcare system with limited resources. Noah Pines offers some cautionary tales, as he reviews the newest launches and previews what's next

Author

Pines, Noah

Subjects
Bristol-Myers Squibb Co., Xeloda (Medication), Perjeta (Medication), Eloxatin (Medication), Rituxan (Medication), Tarceva (Medication), Herceptin (Medication), Alimta (Medication), Zelboraf (Medication), Velcade (Medication), Gleevec (Medication), Avastin (Medication), Erbitux (Medication), Drug therapy, Health care industry, Cancer treatment, Melanoma -- Drug therapy, Cancer patients -- Drug therapy, Pharmaceutical industry, Antineoplastic agents, Biological products industry, Cancer -- Care and treatment, Antimitotic agents
Abstract

In cancer medicine, precision-guided technology is the name of the game. Take Roche's Genentech unit. The company has launched three anti-cancer medicines in the past 10 months, and two were [...]

Published
2012

44. Shifting specialties: new developments in specialty pharma are changing the way manufacturers, payers, docs and patients interact. Ben Comer looks at where things are headed

Author

Comer, Ben

Subjects
Aranesp (Medication), Remicade (Medication), Herceptin (Medication), Humira (Medication), Neulasta (Medication), Copaxone (Medication), MabThera (Medication), Enbrel (Medication), Atripla (Medication), Eryp (Medication), Epogen (Medication), Gleevec (Medication), Truvada (Medication), Avastin (Medication), Tazotere (Medication), Market size, Growth, Forecasts and trends, Industry forecasts, Company growth, Market trend/market analysis, Drugs -- Market size -- Growth -- Forecasts and trends, Pharmaceutical industry -- Market size -- Growth -- Industry forecasts
Abstract

Specialty product sales are growing at a time when breaking even in other areas feels like success. New technological discoveries in drug delivery and mechanism of action have helped to [...]

Published
2010

46. Analysis: HIV/AIDS and Gleevec update

Subjects
Gleevec (Medication), AIDS (Disease) -- Prevention, Cancer -- Care and treatment, Public radio, Medical research, Medicine, Experimental, Antimitotic agents, Antineoplastic agents
Abstract

JOE PALCA, host: This is TALK OF THE NATION/SCIENCE FRIDAY from NPR News. And I'm Joe Palca sitting in for Ira Flatow. Later in the hour, we'll take a look […]

Published
2004

47. Therapeutic focus: oncology

Author

McCaffrey, Kevin

Subjects
American Society of Clinical Oncology, Xtandi (Medication), Revlimid (Medication), Imbruvica (Medication), Rituxan (Medication), Herceptin (Medication), Alimta (Medication), Ibrance (Medication), Opdivo (Medication), Gleevec (Medication), Lynparza (Medication) -- Health aspects, Keytruda (Medication) -- Health aspects, Avastin (Medication), Health aspects, Immunotherapy -- Health aspects
Abstract

Post-ASCO, the oncology space remains one of pharma's most reliable sources of innovation. Our reporter on the scene shares his most essential takeaways. When a raft of doctors, scientists, and [...]

Published
2017

48. Target: cancer: today's astonishing disease-fighting drugs and therapies are giving hope--and the possibility of a long, healthy life--to thousands of patients. Elizabeth Mitchell goes behind the scenes with oncologists, drug companies, and the science of optimism

Author

Mitchell, Elizabeth

Subjects
Gleevec (Medication), Herceptin (Medication), Breast cancer -- Care and treatment, Cancer -- Care and treatment, Agglutinins, Clinical trials
Abstract

Carol Turtur, 55, would rather be skiing. Or better yet, heading down the Danube by boat. But this January morning in 2006, all vacation plans are on hold. The former […]

Published
2007

49. Q3 2017 Sun Pharmaceutical Industries Ltd Earnings Call - Final

Subjects
United States. Food and Drug Administration, Novartis Japan KK, Pharmaceutical industry, Business, Gleevec (Medication)
Abstract

Presentation OPERATOR: Good day, ladies and gentlemen, and a very warm welcome to the Sun Pharmaceutical Industries Limited Q3 FY 2017 earnings conference call. As a reminder, all participant lines [...]

Published
2017

50. Event Brief of Q3 2016 Novartis AG Earnings Call - Final

Subjects
Novartis Pharma AG -- Conferences, meetings and seminars -- Company sales and earnings, Novartis AG -- Conferences, meetings and seminars -- Company sales and earnings, Societe Generale S.A. -- Conferences, meetings and seminars -- Company sales and earnings, Banking industry -- Conferences, meetings and seminars -- Company sales and earnings, Pharmaceutical industry -- Conferences, meetings and seminars -- Company sales and earnings, Company earnings/profit, Banking industry, Business, Cosentyx (Medication), Entresto (Medication), Tasigna (Medication), Gleevec (Medication)
Abstract

CORPORATE PARTICIPANTS . Joe Jimenez - Novartis AG,CEO . Samir Shah - Novartis AG,IR . Harry Kirsch - Novartis AG,CFO . Vas Narasimhan - Novartis AG,Global Head of Drug Development [...]

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results